Vanguard Group’s Immix Biopharma IMMX Stock Holding History

Vanguard Group’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.73M	Buy	1,095,814 +365,652	+50%	+$1.5M	﹤0.01%	3204
2025 Q3	$1.53M	Buy	730,162 +31,625	+5%	+$75.9K	﹤0.01%	3661
2025 Q2	$1.45M	Hold	698,537	–	–	﹤0.01%	3643
2025 Q1	$1.17M	Hold	698,537	–	–	﹤0.01%	3664
2024 Q4	$1.54M	Hold	698,537	–	–	﹤0.01%	3639
2024 Q3	$1.04M	Buy	698,537 +100,000	+17%	+$201K	﹤0.01%	3764
2024 Q2	$1.19M	Buy	598,537 +142,351	+31%	+$327K	﹤0.01%	3735
2024 Q1	$1.4M	Buy	456,186 +295,788	+184%	+$1.15M	﹤0.01%	3704
2023 Q4	$1.11M	Buy	160,398 +54,188	+51%	+$245K	﹤0.01%	3794
2023 Q3	$363K	Buy	106,210 +853	+0.8%	+$2K	﹤0.01%	4146
2023 Q2	$283K	Hold	105,357	–	–	﹤0.01%	4251
2023 Q1	$192K	Hold	105,357	–	–	﹤0.01%	4325
2022 Q4	$241K	Buy	105,357 +232	+0.2%	+$309	﹤0.01%	4271
2022 Q3	$143K	Buy	105,125 +54,220	+107%	+$118K	﹤0.01%	4461
2022 Q2	$132K	Buy	+50,905	New	+$99.4K	﹤0.01%	4517

Other funds holding IMMX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group's IMMX Position: Q4 2025 in Review

Vanguard Group increased its Immix Biopharma (IMMX) stake by 50% in Q4 2025, buying an estimated $1.5M and bringing the position to 1,095,814 shares worth $5.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3204.

Vanguard Group first reported a position in IMMX in Q2 2022 and has held it in 15 quarters since. 67 funds tracked by Wall St. Rank hold IMMX as of Q4 2025.

Vanguard Group held 1,095,814 shares of Immix Biopharma worth $5.73M as of Q4 2025.
Vanguard Group bought 365,652 Immix Biopharma shares in Q4 2025, an estimated $1.5M.
Immix Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3204 holding.
Vanguard Group first reported a position in Immix Biopharma in Q2 2022 and has held it in 15 quarters since.
67 funds tracked by Wall St. Rank held Immix Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.